Cargando…

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

BACKGROUND: Epidemiologic studies have suggested that hypertriglyceridemia and insulin resistance are related to the development of colon cancer. Nuclear peroxisome proliferator-activated receptors (PPAR), which play a central role in lipid and glucose metabolism, had been hypothesized as being invo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tenenbaum, Alexander, Boyko, Valentina, Fisman, Enrique Z, Goldenberg, Ilan, Adler, Yehuda, Feinberg, Micha S, Motro, Michael, Tanne, David, Shemesh, Joseph, Schwammenthal, Ehud, Behar, Solomon
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440374/ https://www.ncbi.nlm.nih.gov/pubmed/18565233 http://dx.doi.org/10.1186/1475-2840-7-18

Ejemplares similares

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment
por: Node, Koichi, et al.
Publicado: (2009)

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
por: Tenenbaum, Alexander, et al.
Publicado: (2005)

Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
por: Arbel, Yaron, et al.
Publicado: (2016)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Statins research unfinished saga: desirability versus feasibility
por: Fisman, Enrique Z, et al.
Publicado: (2005)

Losartan and diabetic nephropathy: commentaries on the RENAAL study
por: Fisman, Enrique Z, et al.
Publicado: (2002)

Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof
por: Fisman, Enrique Z, et al.
Publicado: (2003)

Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns
por: Shemesh, Joseph, et al.
Publicado: (2013)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
por: Klempfner, Robert, et al.
Publicado: (2012)

Cessation of Bezafibrate in patients with chronic kidney disease improves renal function
por: Zingerman, Boris, et al.
Publicado: (2020)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model
por: Saha, Lekha, et al.
Publicado: (2014)

Metabolic effects of bezafibrate in mitochondrial disease
por: Steele, Hannah, et al.
Publicado: (2020)

Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease
por: Younis, Arwa, et al.
Publicado: (2016)

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study
por: Younis, Arwa, et al.
Publicado: (2017)

Antidiabetic Action of Bezafibrate in a Large Observational Database
por: Flory, James H., et al.
Publicado: (2009)

I-3 Treatment of CPT2 deficiency with bezafibrate
por: Laforet, P.
Publicado: (2011)

Bezafibrate prevents aging in in vitro-matured porcine oocytes
por: Kim, Ju-Yeon, et al.
Publicado: (2021)

Anemia status, hemoglobin concentration and outcome after acute stroke: a cohort study
por: Tanne, David, et al.
Publicado: (2010)

Pseudo-discordance mimicking low-flow low-gradient aortic stenosis in transcatheter aortic valve replacement patients with severe symptomatic aortic stenosis
por: Kuperstein, Rafael, et al.
Publicado: (2022)

Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2017)

Annual acknowledgement of manuscript reviewers
por: Tenenbaum, Alexander, et al.
Publicado: (2013)

Annual acknowledgement of manuscript reviewers
por: Tenenbaum, Alexander, et al.
Publicado: (2014)

Acknowledgement of manuscript reviewers 2014
por: Fisman, Enrique, et al.
Publicado: (2015)

Investigation of novel material for effective photodegradation of bezafibrate in aqueous samples
por: Regulska, Elżbieta, et al.
Publicado: (2014)

Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Xu, Si-Chi, et al.
Publicado: (2017)

Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency
por: Suyama, Tomonori, et al.
Publicado: (2020)

Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice
por: Franko, Andras, et al.
Publicado: (2022)

Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry
por: Steiner, Hillel, et al.
Publicado: (2016)

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
por: Tenenbaum, Alexander, et al.
Publicado: (2004)

The ubiquitous interleukin-6: a time for reappraisal
por: Fisman, Enrique Z, et al.
Publicado: (2010)

"The metabolic syndrome... is dead": These reports are an exaggeration
por: Tenenbaum, Alexander, et al.
Publicado: (2011)

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study
por: Tenenbaum, Alexander, et al.
Publicado: (2010)

A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease
por: Fisman, Enrique Z, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_1f53mksa1sphe5t7ijev6v0ers